News for Pharma Mar, S.A. (PHMMF)

PR NewswireDUBLIN, April 23, 2025 Statistically significant and clinically meaningful progression-free survival (PFS) and overall survival (OS) data for Ze

Data from multiple studies of investigational bispecific drug zanidatamab, including pivotal Phase 2 biliary tract cancers (BTC) trial results, demonstrate...

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present five new abstracts at the...

Pharma Mar, S.A. (OTCPK:PHMMF) Q4 2022 Earnings Conference Call March 1, 2023 7:00 AM ETCompany ParticipantsJose Luis - Head, Investor Relations & Capital MarketsMaria Luisa de Francia...

Read Pharma Mar, S.A. (OTCMKTS:PHMMF) Sees Significant Increase in Short Interest at ETF Daily News

Read Pharma Mar, S.A. (OTCMKTS:PHMMF) Short Interest Up 1,400.0% in May at ETF Daily News

Read Short Interest in Pharma Mar, S.A. (OTCMKTS:PHMMF) Declines By 86.7% at ETF Daily News

Read Short Interest in Pharma Mar, S.A. (OTCMKTS:PHMMF) Rises By 200.0% at ETF Daily News

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the first patient was enrolled in EMERGE-201, a Phase 2 clinical trial evaluating the...

Pharma Mar, S.A. (OTCPK:PHMMF) Q4 2021 Results Conference Call March 01, 2022 07:00 AM ET Company Participants Jose Luis Moreno - Head, IR and Capital Markets Luis Mora - Managing Director...